Paraquat Lawsuit: Where the Parkinson's Litigation Stands

Most mass torts move case by case toward eventual settlement. This one has a different structure entirely: a single pending ruling on whether paraquat can cause Parkinson’s disease at all could resolve thousands of cases in one stroke, in either direction. Understanding that ruling is understanding most of what matters about this litigation right now.

Quick answer: Plaintiffs allege long-term paraquat exposure increases Parkinson’s disease risk and that manufacturers Syngenta and Chevron Phillips failed to warn. Federal cases are consolidated as MDL No. 3004 before Chief Judge Nancy Rosenstengel in the Southern District of Illinois, with a parallel docket in Philadelphia’s state mass tort program. A narrow 2021 settlement (~$187.5 million) resolved only a small group of cases; a broader framework “agreed in principle” in spring 2025 is still not finalized. The judge’s pending Daubert ruling on general causation — whether paraquat can cause Parkinson’s at all — is the single event most likely to determine this litigation’s direction next.

What the Litigation Alleges

Paraquat is a widely used agricultural herbicide. Plaintiffs allege that long-term occupational or agricultural exposure increases the risk of developing Parkinson’s disease, and that manufacturers knew or should have known of this risk — citing EPA assessments and published research — and failed to adequately warn users. The manufacturers dispute that the available science establishes causation at all, arguing the studies plaintiffs rely on show, at most, correlation rather than a demonstrated causal link.

Where the Litigation Actually Stands

• MDL No. 3004, In re: Paraquat Products Liability Litigation, centralized on June 7, 2021, in the U.S. District Court for the Southern District of Illinois before Chief Judge Nancy J. Rosenstengel.
• A parallel state-court docket is coordinated in the Philadelphia Court of Common Pleas under Pennsylvania’s mass tort program, separate from but proceeding alongside the federal MDL.
• Defendants primarily include Syngenta, paraquat’s manufacturer, and Chevron Phillips Chemical Company, its longtime U.S. distributor and formulator.
• Thousands of cases pending across both dockets combined, among the larger current federal mass torts by case count.

See our explainer on how mass tort litigation actually works for what an MDL is and how a state-court mass tort program like Philadelphia’s can proceed alongside, rather than instead of, the federal litigation.

The 2021 Settlement Was Narrow, Not Global

In June 2021, Syngenta agreed to pay approximately $187.5 million to resolve a limited group of state-court cases filed in California and Illinois — a small fraction of the litigation as it exists today, not a settlement of the broader MDL or the Parkinson’s claims generally. Treating this figure as evidence of what the overall litigation is “worth,” or as proof that a general settlement fund already exists, would be a mistake.

The 2025 Framework: “Agreed in Principle” Is Not “Finalized”

In spring 2025, the parties announced a broader settlement framework agreed in principle, covering more of the pending docket than the 2021 settlement did. As of this writing, that framework has not been fully finalized — reporting indicates some plaintiffs’ firms have raised objections to specific terms, leaving the deal short of complete sign-off.

This is the same distinction our guide to Depo-Provera meningioma lawsuit status draws for a different litigation: an announced framework is real progress, but it is not the same as a settlement that is actually funded and being paid out.

The Ruling That Could Decide Thousands of Cases at Once

Most of the mass torts covered on this site are litigated with causation decided case by case, or through a settlement negotiated once enough cases have gone through bellwether trials. This litigation has a different, more concentrated pressure point: a Daubert ruling on general causation.

A Daubert ruling decides whether an expert’s scientific testimony is reliable enough to be presented to a jury at all. Here, the judge’s pending ruling addresses a threshold scientific question common to the entire docket: whether paraquat is capable of causing Parkinson’s disease at all, independent of any individual plaintiff’s specific facts. If the court excludes plaintiffs’ general-causation experts, a substantial share of the pending cases — reported in the thousands — could face dismissal at once. If the court allows that testimony, those cases proceed toward the individual causation and damages questions that would normally follow.

This concentration of consequence in a single ruling is genuinely distinctive, and it is the main reason this litigation’s near-term direction is harder to predict than a mass tort moving through ordinary bellwether trials.

Building an Individual Claim

• A documented exposure history — employment records, pesticide application logs, agricultural work records, or purchase records identifying the specific product and manufacturer
• A Parkinson’s disease diagnosis, with neurological treatment records establishing onset and progression
• A clear timeline connecting the exposure period to the eventual diagnosis, since Parkinson’s disease develops gradually and exposure frequently occurred years before symptoms appeared

Practical Steps

1. Document your paraquat exposure history now — employer records, application logs, and the specific product and manufacturer used, if known.
2. Gather complete neurological treatment records establishing your Parkinson’s disease diagnosis and its progression.
3. Do not assume the 2021 settlement or the 2025 framework already covers your claim — neither is a general fund you can simply apply to.
4. Check current status before assuming a specific outcome, since the pending causation ruling could materially change the litigation’s direction in either direction.
5. Consult an attorney handling paraquat claims specifically, given how much currently turns on a single pending scientific ruling rather than routine case-by-case litigation.

Sources & Further Reading

• U.S. District Court, Southern District of Illinois — docket for MDL No. 3004, In re: Paraquat Products Liability Litigation
• Philadelphia Court of Common Pleas mass tort program — the parallel state-court paraquat docket
• EPA human health risk assessments for paraquat dichloride, cited by plaintiffs in the general-causation dispute
• See our explainer on how mass tort litigation actually works for the MDL framework this litigation runs on, and Depo-Provera meningioma lawsuit status for another current litigation where an announced settlement framework has not yet been finalized